Blitz Bureau
Antimicrobial resistance has long been a growing global concern, with pharmaceutical companies striving to develop new medicines to combat it worldwide. Despite years of challenges and relentless effort, a breakthrough has finally emerged. After three decades of research and hard work, India has led the way with the creation of Nafithromycin, the country’s first indigenous macrolide antibiotic.
This remarkable achievement marks a pivotal moment in the fight against antimicrobial resistance, showcasing India’s growing capabilities in pharmaceutical innovation.
Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi and parasites no longer respond to antimicrobial medicines. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become difficult or impossible to treat, increasing the risk of disease spread, severe illness, disability and death.
While AMR is a natural process driven by genetic changes in pathogens over time, its spread is significantly accelerated by human activities, particularly the overuse and misuse of antimicrobial drugs in humans, animals, and plants. Antimicrobial resistance (AMR) has become a major global health issue, with around six lakh lives lost in India each year due to resistant infections.
However, India is making significant strides in addressing AMR, particularly through the development of new drugs. Nafithromycin, developed with Rs8crore in funding under the Biotechnology Industry Research Assistance Council (BIRAC) Biotech Industry Programme for Phase 3 clinical trials, is a key milestone in this effort. Since India carries a large share of the global pneumonia burden, introducing Nafithromycin is especially important, as there have been no new antibiotics in recent years.
Short recovery time
Nafithromycin, was officially launched on in November last year by Union Minister Dr. Jitendra Singh. Developed by Wockhardt with support from BIRAC, Nafithromycin, marketed as ‘Miqnaf’, targets Community-Acquired Bacterial Pneumonia (CABP) caused by drugresistant bacteria, which disproportionately affects vulnerable populations such as children, the elderly, and those with compromised immune systems.
This ground-breaking antibiotic is ten times more effective than current treatments like azithromycin and offers a three-day treatment regimen, significantly shortening the recovery time while improving patient outcomes.
Nafithromycin is designed to treat both typical and atypical drug-resistant bacteria, making it a crucial tool in addressing the global health crisis of AMR (Anti-microbial Resistance). It boasts superior safety, minimal side effects, and no significant drug interactions. Nafithromycin’s development marks a historic milestone as the first new antibiotic in its class to be introduced globally in over 30 years. The drug, which has undergone extensive clinical trials across the US, Europe, and India, has been developed with an investment of ₹500 crores and is now awaiting final approval from the Central Drugs Standard Control Organisation (CDSCO).
